Stay updated on Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.

Latest updates to the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedRevision: v3.4.2 was applied, replacing the previous v3.4.1. This update seems to be a metadata/version change with no visible impact on study details or page content.SummaryDifference0.0%

- Check15 days agoChange DetectedRevision: v3.4.1 was added and Revision: v3.4.0 was removed, indicating a minor internal software update with no changes to page content or trial information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check23 days agoChange DetectedAdds a glossary toggle and new update timestamp labels (Last Update Submitted that Met QC Criteria and Last Update Posted) to the study details page, while removing the older QC label, the 'Last Update Posted (Estimated)' tag, the 'No FEAR Act data' wording, and the previous revision tag (v3.3.4).SummaryDifference0.1%

- Check37 days agoChange DetectedThe page shows a minor site revision from v3.3.3 to v3.3.4 with no changes to study content or page behavior. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check65 days agoChange DetectedExpanded the study Locations to include numerous sites across the US, Canada, Europe, and Australia, with many regional entries added and others removed.SummaryDifference4%

- Check87 days agoChange DetectedThe only visible change is the page footer showing Revision: v3.3.2 instead of v3.3.1 on the ClinicalTrials.gov page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.